These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24679664)

  • 21. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
    Freudenburg-de Graaf W; Knol MJ; van der Ende A
    Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meningococcal vaccines: Current state and future outlook.
    Leca M; Bornet C; Montana M; Curti C; Vanelle P
    Pathol Biol (Paris); 2015 Jun; 63(3):144-51. PubMed ID: 25986879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances with vaccination against Neisseria meningitidis.
    Borrow R
    Trop Med Int Health; 2012 Dec; 17(12):1478-91. PubMed ID: 22947250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
    Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL
    Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
    Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
    Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H
    Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.
    Esposito S; Castellazzi L; Bosco A; Musio A; Stoddard J
    Immunotherapy; 2014; 6(4):395-408. PubMed ID: 24815780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meningococcal B vaccination: real-world experience and future perspectives.
    Kuhdari P; Stefanati A; Lupi S; Valente N; Gabutti G
    Pathog Glob Health; 2016; 110(4-5):148-56. PubMed ID: 27309042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Group B meningococcal vaccine science and policy.
    Drysdale SB; Pollard AJ
    J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
    Watson PS; Turner DP
    Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
    Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
    Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine].
    Abad R; Martinón-Torres F; Santolaya ME; Banzhoff A; González-Inchausti C; Graña MG; Vázquez JA
    Rev Esp Quimioter; 2019 Jun; 32(3):208-216. PubMed ID: 31148440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment.
    Parikh SR; Newbold L; Slater S; Stella M; Moschioni M; Lucidarme J; De Paola R; Giuliani M; Serino L; Gray SJ; Clark SA; Findlow J; Pizza M; Ramsay ME; Ladhani SN; Borrow R
    Lancet Infect Dis; 2017 Jul; 17(7):754-762. PubMed ID: 28366725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.